Inhibition of microRNA-128-3p alleviates liver ischaemia-reperfusion injury in mice through repressing the Rnd3/NF-


Journal

Innate immunity
ISSN: 1753-4267
Titre abrégé: Innate Immun
Pays: United States
ID NLM: 101469670

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 4 6 2020
medline: 1 10 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

Although liver ischaemia-reperfusion (I/R) injury remains the primary underlying reason for liver transplant failure or post-transplantation liver dysfunction, the underlying mechanism is still largely elusive. MicroRNAs (miRNA) are involved in multiple physiological and pathological processes, including inflammation. Here, we identified that the miR-128-3p/Rho family GTPase 3 (Rnd3)/NF-κB axis might play a critical role in liver I/R injury. Our results demonstrated that the level of miR-128-3p was negatively correlated with the Rnd3 level during liver I/R. Dual luciferase reporter assay results proved that Rnd3 mRNA was a direct target of miR-128-3p. Additionally, Western blotting and quantitative RT-PCR analyses revealed that knock-down of miR-128-3p could up-regulate Rnd3 mRNA and protein levels, thereby suppressing the NF-κB pathway through down-regulating NF-κB p65. Consequently, the serum levels of NF-κB-associated inflammatory factors and aspartate aminotransferase/alanine aminotransferase were decreased. Moreover, overexpression of Rnd3 could reverse the activation of NF-κB caused by miR-128-3p agomir during liver I/R injury. Overall, our study results suggest that repression of miR-128-3p can alleviate liver I/R injury through the miR-128-3p/Rnd3/NF-κB axis and may facilitate the development of novel protective approaches against liver I/R injury.

Identifiants

pubmed: 32486927
doi: 10.1177/1753425920928449
pmc: PMC7491242
doi:

Substances chimiques

MicroRNAs 0
Mirn128 microRNA, mouse 0
NF-kappa B 0
Aspartate Aminotransferases EC 2.6.1.1
Alanine Transaminase EC 2.6.1.2
RND3 protein, human EC 3.6.5.2
rho GTP-Binding Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

528-536

Références

Transplantation. 2010 Jul 27;90(2):142-9
pubmed: 20606606
Pharmacol Res. 2019 Aug;146:104276
pubmed: 31112750
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
Genes Dev. 2012 Feb 1;26(3):203-34
pubmed: 22302935
J Invest Surg. 2014 Dec;27(6):366-79
pubmed: 25058854
Int J Mol Sci. 2019 Mar 30;20(7):
pubmed: 30935055
Liver Int. 2019 May;39(5):788-801
pubmed: 30843314
Nat Commun. 2017 Jun 19;8:15870
pubmed: 28627514
Front Pharmacol. 2019 Oct 08;10:1192
pubmed: 31649546
Biochem Biophys Res Commun. 2020 Jan 1;521(1):98-105
pubmed: 31635801
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Transpl Int. 2015 Jun;28(6):751-60
pubmed: 25611689
Nat Rev Gastroenterol Hepatol. 2013 Feb;10(2):79-89
pubmed: 23229329
Annu Rev Immunol. 2000;18:621-63
pubmed: 10837071
Cancer Res. 2014 Apr 1;74(7):2082-93
pubmed: 24525741
Shock. 2012 Feb;37(2):234-8
pubmed: 22089187
Nat Rev Mol Cell Biol. 2013 Aug;14(8):475-88
pubmed: 23800994
Biosci Rep. 2018 Jul 31;38(4):
pubmed: 29853534
J Neuroinflammation. 2018 Dec 15;15(1):343
pubmed: 30553270
Int Immunopharmacol. 2016 Jun;35:201-209
pubmed: 27064547
Transplant Proc. 2018 Dec;50(10):3831-3839
pubmed: 30577275
Cells. 2019 Sep 23;8(10):
pubmed: 31547621
Front Immunol. 2019 Nov 01;10:2505
pubmed: 31736950
Curr Genomics. 2015 Oct;16(5):359-65
pubmed: 27047256
Liver Int. 2015 Apr;35(4):1172-84
pubmed: 25039534
Oxid Med Cell Longev. 2017;2017:1702967
pubmed: 28367266
Metabolism. 2019 Dec;101:153999
pubmed: 31672447
Virchows Arch. 2005 May;446(5):475-82
pubmed: 15856292
Transplantation. 1993 Jun;55(6):1265-72
pubmed: 7685932
Cell Prolif. 2019 Sep;52(5):e12665
pubmed: 31332862
Int J Mol Sci. 2018 Apr 26;19(5):
pubmed: 29701719
Front Pharmacol. 2017 Oct 30;8:775
pubmed: 29163161
Life Sci. 2020 May 15;249:117517
pubmed: 32147431
J Surg Res. 2008 Jun 1;147(1):153-9
pubmed: 17707862
Hepatology. 2020 Feb 21;:
pubmed: 32080887
Circulation. 2019 Feb 26;139(9):1185-1198
pubmed: 30586715
J Hepatol. 2013 Nov;59(5):1094-106
pubmed: 23811302

Auteurs

Tong Mou (T)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Yunhai Luo (Y)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Zuotian Huang (Z)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Daofeng Zheng (D)

West China Hospital, Sichuan University, PR China.

Xingyu Pu (X)

West China Hospital, Sichuan University, PR China.

Ai Shen (A)

Hepatobiliary Pancreatic Tumour Centre, Chongqing University Cancer Hospital, PR China.

Junliang Pu (J)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Tingting Li (T)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Jiangwen Dai (J)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Wei Chen (W)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Zhongjun Wu (Z)

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, PR China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH